Literature DB >> 22415526

The impact of portal vein resection on outcomes for hilar cholangiocarcinoma: a multi-institutional analysis of 305 cases.

Mechteld C de Jong1, Hugo Marques, Bryan M Clary, Todd W Bauer, J Wallis Marsh, Dario Ribero, Pietro Majno, Ioannis Hatzaras, Dustin M Walters, Andrew S Barbas, Raquel Mega, Richard D Schulick, Michael A Choti, David A Geller, Eduardo Barroso, Gilles Mentha, Lorenzo Capussotti, Timothy M Pawlik.   

Abstract

UNLABELLED: BACKGROUND. Surgical strategy for hilar cholangiocarcinoma often includes hepatectomy, but the role of portal vein resection (PVR) remains controversial. In this study, the authors sought to identify factors associated with outcome after surgical management of hilar cholangiocarcinoma and examined the impact of PVR on survival.
METHODS: Three hundred five patients who underwent curative-intent surgery for hilar cholangiocarcinoma between 1984 and 2010 were identified from an international, multi-institutional database. Clinicopathologic data were evaluated using univariate and multivariate analyses.
RESULTS: Most patients had hilar cholangiocarcinoma with tumors classified as T3/T4 (51.1%) and Bismuth-Corlette type II/III (60.9%). Resection involved extrahepatic bile duct resection (EHBR) alone (26.6%); or hepatectomy and EHBR without PVR (56.7%); or combined hepatectomy, EHBR, and PVR (16.7%). Negative resection (R0) margin status was higher among the patients who underwent hepatectomy plus EHBR (without PVR, 64.2%; with PVR, 66.7%) versus EHBR alone (54.3%; P < .001). The median number of lymph nodes assessed was higher among the patients who underwent hepatectomy plus EHBR (without PVR, 6 lymph nodes; with PVR, 4 lymph nodes) versus EHBR alone (2 lymph nodes; P < .001). The 90-day mortality rate was lower for patients who underwent EHBR alone (1.2%) compared with the rate for patients who underwent hepatectomy plus EHBR (without PVR, 10.6%, with PVR, 17.6%; P < .001). The overall 5-year survival rate was 20.2%. Factors that were associated with an adverse prognosis included lymph node metastasis (hazard ratio [HR], 1.79; P = .002) and R1 margin status (HR, 1.81; P < .001). Microscopic vascular invasion did not influence survival (HR, 1.23; P = .19). Among the patients who underwent hepatectomy plus EHBR, PVR was not associated with a worse long-term outcome (P = .76).
CONCLUSIONS: EHBR alone was associated with a greater risk of positive surgical margins and worse lymph node clearance. The current results indicated that hepatectomy should be considered the standard treatment for hilar cholangiocarcinoma, and PVR should be undertaken when necessary to extirpate all disease. Combined hepatectomy, EHBR, and PVR can offer long-term survival in some patients with advanced hilar cholangiocarcinoma.
Copyright © 2012 American Cancer Society.

Entities:  

Mesh:

Year:  2012        PMID: 22415526     DOI: 10.1002/cncr.27492

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  66 in total

1.  Bile duct surgery in the treatment of hepatobiliary and gallbladder malignancies: effects of hepatic and vascular resection on outcomes.

Authors:  Perry Shen; Nora Fino; Edward A Levine; Pamela Eversole; Clancy Clark
Journal:  HPB (Oxford)       Date:  2015-09-16       Impact factor: 3.647

2.  Regional thermochemotherapy versus hepatic arterial infusion chemotherapy for palliative treatment of advanced hilar cholangiocarcinoma: a retrospective controlled study.

Authors:  Yaoting Chen; Huiqing Li; Xiongying Jiang; Dong Chen; Jiayan Ni; Hongliang Sun; Jianghong Luo; Herui Yao; Linfeng Xu
Journal:  Eur Radiol       Date:  2016-01-28       Impact factor: 5.315

3.  Risk factors, management, and prognosis for liver abscess after radical resection of hilar cholangiocarcinoma.

Authors:  Changxi Zhang; Tao Li; Zhiqiang Chen; Qiangpu Chen; Xuting Zhi
Journal:  Int J Clin Exp Med       Date:  2015-11-15

4.  Principles of surgical resection in hilar cholangiocarcinoma.

Authors:  Emilio Ramos
Journal:  World J Gastrointest Oncol       Date:  2013-07-15

Review 5.  Cholangiocarcinoma 2020: the next horizon in mechanisms and management.

Authors:  Jesus M Banales; Jose J G Marin; Angela Lamarca; Pedro M Rodrigues; Shahid A Khan; Lewis R Roberts; Vincenzo Cardinale; Guido Carpino; Jesper B Andersen; Chiara Braconi; Diego F Calvisi; Maria J Perugorria; Luca Fabris; Luke Boulter; Rocio I R Macias; Eugenio Gaudio; Domenico Alvaro; Sergio A Gradilone; Mario Strazzabosco; Marco Marzioni; Cédric Coulouarn; Laura Fouassier; Chiara Raggi; Pietro Invernizzi; Joachim C Mertens; Anja Moncsek; Sumera Rizvi; Julie Heimbach; Bas Groot Koerkamp; Jordi Bruix; Alejandro Forner; John Bridgewater; Juan W Valle; Gregory J Gores
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2020-06-30       Impact factor: 46.802

6.  Improved surgical outcomes for hilar cholangiocarcinoma: changes in surgical procedures and related outcomes based on 40 years of experience at a single institution.

Authors:  Ryota Higuchi; Takehiro Ota; Takehisa Yazawa; Hideki Kajiyama; Tatsuo Araida; Toru Furukawa; Tatsuya Yoshikawa; Ken Takasaki; Masakazu Yamamoto
Journal:  Surg Today       Date:  2015-02-05       Impact factor: 2.549

7.  Our Rationale of Initiating Neoadjuvant Chemotherapy for Hilar Cholangiocarcinoma: A Proposal of Criteria for "Borderline Resectable" in the Field of Surgery for Hilar Cholangiocarcinoma.

Authors:  Ryusei Matsuyama; Daisuke Morioka; Ryutaro Mori; Yasuhiro Yabushita; Seigo Hiratani; Yohei Ota; Takafumi Kumamoto; Itaru Endo
Journal:  World J Surg       Date:  2019-04       Impact factor: 3.352

8.  Defining Early Recurrence of Hilar Cholangiocarcinoma After Curative-intent Surgery: A Multi-institutional Study from the US Extrahepatic Biliary Malignancy Consortium.

Authors:  Xu-Feng Zhang; Eliza W Beal; Jeffery Chakedis; Qinyu Chen; Yi Lv; Cecilia G Ethun; Ahmed Salem; Sharon M Weber; Thuy Tran; George Poultsides; Andre Y Son; Ioannis Hatzaras; Linda Jin; Ryan C Fields; Stefan Buettner; Charles Scoggins; Robert C G Martin; Chelsea A Isom; Kamron Idrees; Harveshp D Mogal; Perry Shen; Shishir K Maithel; Carl R Schmidt; Timothy M Pawlik
Journal:  World J Surg       Date:  2018-09       Impact factor: 3.352

Review 9.  The Surgical Management of Klatskin Tumours: Has Anything Changed in the Last Decade?

Authors:  Neil Bhardwaj; Giuseppe Garcea; Ashley R Dennison; Guy J Maddern
Journal:  World J Surg       Date:  2015-11       Impact factor: 3.352

10.  En bloc resection of the hepatoduodenal ligament for advanced biliary malignancy.

Authors:  Yuji Kaneoka; Atsuyuki Maeda; Masatoshi Isogai
Journal:  J Gastrointest Surg       Date:  2015-01-06       Impact factor: 3.452

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.